Hints and tips:
...Eric Farnsworth, who heads the Washington office of the Council of the Americas, a regional business group, said there was growing bipartisan concern about the lack of an active US trade agenda for Latin...
...Another former classmate recalled that it was a different brilliant Yale athlete, football player Eric Johnson, who friends expected would go on to great things....
...though its balance sheet is smaller than rivals such as JPMorgan and Bank of America, it has tapped its relationship with Japan’s Mitsubishi UFJ to finance huge loans before, including $33.5bn for Bristol-Myers...
...It exited its position in generic drugs maker Teva and sold more than 70 per cent of its remaining shares in AbbVie and Bristol-Myers Squibb....
...All assets may perform badly under stagflation, but we’d rather own Pepsi, Johnson & Johnson, Kimberly-Clark, Bristol-Myers et al than sit and watch our cash lose its earnings power....
...The scale of the damage was still undetermined at press time, but the virtual levelling of the beachfront town of Fort Myers suggests it will be costly, both in terms of dollars and in human life....
...Solidcore secured a fundraising this February, capital its chief executive Bryan Myers said would give it the “fuel” to grow and sign new leases....
...Berkshire reduced its stakes in drugmakers including Merck, Bristol-Myers Squibb and AbbVie in the first quarter, cut more than half of its holding in oil major Chevron, and sold the entirety of its positions...
...Myers, Corona del Mar, California...
...It increased its stakes in AbbVie, Bristol-Myers Squibb and Merck, but sold out of Pfizer....
...Berkshire’s new stake accounted for 1.3 per cent of Bristol-Myers shares outstanding, 1.2 per cent of AbbVie, 0.9 per cent of Merck and less than 0.1 per cent of Pfizer....
...I’m glad to see that Bret Stephens is with me on Eric Adams and why New York needs him....
...Early last year Bristol-Myers Squibb purchased Celgene for $93bn, while Pfizer snapped up Array BioPharma for $11bn in June....
...The two biggest takeovers clinched this year clocked in just below $8bn, a fraction of the $93.4bn acquisition of Celgene by drugmaker Bristol-Myers Squibb that was agreed in the first few days of 2019....
...Bristol-Myers also announced that it plans to buy back $7bn worth of shares, up from the previously planned $5bn share repurchase....
...While those takeovers do not generate the same fanfare as marquee transactions such as Bristol-Myers Squibb’s $93.4bn takeover of rival drugmaker Celgene, they are critical fee generators for advisers....
...The deals were broad-based, spanning transformative pharmaceutical acquisitions like Bristol-Myers Squibb’s $93bn purchase of rival drugmaker Celgene and AbbVie’s buyout of Allergan for $84bn, and industrial...
...He joins from O’Melveny and Myers....
...Check out the full story from DD’s Eric Platt and James Fontanella-Khan....
...“We believe the risks inherent in this acquisition paired with the long-term poor results at Bristol-Myers make it untenable to support such a transaction.”...
...“The deal has strategic rationale and importantly Bristol-Myers is not a realistic take-out candidate,” he said, adding that he believed Bristol-Myers shareholders would vote on April 12 to back the deal...
...Bristol-Myers Squibb’s $90bn takeover of Celgene, struck in the first few days of January, helped unleash a wave of pharma deals this year....
...“The transaction will ensure that Bristol-Myers Squibb’s strong growth continues for the foreseeable future.”...
...Elizabeth Mily has joined Bristol-Myers Squibb as executive vice-president of strategy and business development. Mily joins from Barclays, where she was a managing director and chair of life sciences....
International Edition